Australian regulation of autologous human cell and tissue products: implications for commercial stem cell clinics

Narcyz Ghinea, Megan Munsie, Christopher Rudge, Cameron Stewart

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

In 2018, Australia's Therapeutic Goods Administration introduced regulatory reforms that set stricter criteria around the regulation of products derived from a patient's own cells and tissues, posing significant implications for clinics offering stem cell treatments. We review the regulatory framework and discuss its potential commercial implications, including the ambiguities that may arise from it in practice, as well as the likely impact it will have on product development and advertising practices in the future.

Original languageEnglish
Pages (from-to)1361-1369
Number of pages9
JournalRegenerative Medicine
Volume15
Issue number2
DOIs
Publication statusPublished - Feb 2020

Keywords

  • Australia
  • autologous stem cell-based interventions
  • commercial stem cell clinics
  • human cell and tissue products
  • law
  • legal regulation
  • regulation of biologicals
  • regulatory framework

Fingerprint

Dive into the research topics of 'Australian regulation of autologous human cell and tissue products: implications for commercial stem cell clinics'. Together they form a unique fingerprint.

Cite this